New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Moderna, Inc.

MRNA

Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.

Revenue
+29.2%
EPS
n/m
Free cash flow
n/m
Total debt
+13,550.0%

Quarter to September 2026, against a year earlier

195.12 4.21 −2.11%

After hours trading: 199.30, up 2.14%, last trade Fri 7:57pm Eastern.

Market cap
$79.6B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
3/9
ROIC
−35.1%
Net debt / EBITDA
1.8×
Payout ratio
—

Moderna, Inc. (MRNA) P/S ratio

Alert me on P/S ratio

As of Nov 20, 2026, Moderna, Inc. (MRNA) trades at a P/S ratio of 31.0×. Over the past ten years it has ranged from 2.0× (September 2022) to 543× (May 2020); the current reading is higher than 72% of that period. That is above the Biotechnology industry median of 8.6× and above the Healthcare sector median of 3.2×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 5.9× 19.60%
FY2024 4.9× (21.38%)
FY2023 6.3× 71.42%
FY2022 3.7× (33.93%)
FY2021 5.5× (88.82%)
FY2020 49.6× (54.06%)
FY2019 108× 1,076.69%
FY2018 9.2× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/S ratio Change
Sep 2026 30.6× 144.47%
Jun 2026 12.5× 38.71%
Mar 2026 9.0× 52.83%
Dec 2025 5.9× 30.75%
31 more quarters

Against its own ten years

Low 2.0× High 543×
Ten-year median 8.5×
Current reading's percentile 72

P/S ratio against peers

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on MRNA